COMORBIDITY AS A FACTOR OF PROGNOSIS IN MULTIPLE MYELOMA
(Abstract release date: 05/19/16)
EHA Library. Skvortsova N. 06/09/16; 134893; PB1993
Natalia Skvortsova
Contributions
Contributions
Abstract
Abstract: PB1993
Type: Publication Only
Background
Despite the modern possibilities of therapy, multiple myeloma (MM) is an incurable disease with a wide variety of outcomes, depending on the presence of risk factors. MM Classification based on the criteria of Durie/Salmon and the ISS, include, primarily, the risk factors associated with the disease itself. However, factors associated with the patient, such as co-morbidities and organ dysfunction which further affect the outcome of the tumor, is still not fully integrated into the predictive model.
Aims
To analyze the effect of prognostic factors: age, sex, medical condition and comorbidities, as well as indices of comorbidity and Sharlson Freiburger, overall survival (OS) in patients with MM.
Methods
206 patients with MM (91 men and 115 women) analyzed. Patients ranged in age from 36 to 81 years (median 68 years). The statistical analysis was used software package SPSS 23. Effect of studied factors on the long-term prognosis was estimated by odds ratios (confidence interval 0.95). In developing the model predicting the likelihood of an unfavorable outcome were used methods of correlation, factor and regression analysis.
Results
during the factor analysis, all investigated prognostic factors, such as somatic status, GFR <30 mL / min / 1.73 m2, the presence of any tumor or metastasis of solid tumors, and had a significant effect on the agents. The prevalence of comorbidity in patients with MM at diagnosis was - 80%. The most common diseases have been associated disease of the gastrointestinal tract (88.4%), cardiovascular (78.6%), urinary (44.5%) and endocrine systems (26.8%). In assessing the prognostic impact on overall survival and an index of comorbidity Sharlson Freiburger index shows that both indices significantly affect the survival of patients with MM, depending on the increase in their score on the scales (P <0.001). Median survival in the evaluation of Freiburger index was 55.0, 29.5 and 19.5 months for 0, 1 and 2-3 scores, respectively. Sharlson comorbidity index also indicated a significant difference in the survival rate of patients corresponding to 0, 1-2, and ≥3 points.
Conclusion
so comorbidity patients affects the survival and effectiveness of treatment in patients with MM, reducing these figures.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma, Prognostic factor
Type: Publication Only
Background
Despite the modern possibilities of therapy, multiple myeloma (MM) is an incurable disease with a wide variety of outcomes, depending on the presence of risk factors. MM Classification based on the criteria of Durie/Salmon and the ISS, include, primarily, the risk factors associated with the disease itself. However, factors associated with the patient, such as co-morbidities and organ dysfunction which further affect the outcome of the tumor, is still not fully integrated into the predictive model.
Aims
To analyze the effect of prognostic factors: age, sex, medical condition and comorbidities, as well as indices of comorbidity and Sharlson Freiburger, overall survival (OS) in patients with MM.
Methods
206 patients with MM (91 men and 115 women) analyzed. Patients ranged in age from 36 to 81 years (median 68 years). The statistical analysis was used software package SPSS 23. Effect of studied factors on the long-term prognosis was estimated by odds ratios (confidence interval 0.95). In developing the model predicting the likelihood of an unfavorable outcome were used methods of correlation, factor and regression analysis.
Results
during the factor analysis, all investigated prognostic factors, such as somatic status, GFR <30 mL / min / 1.73 m2, the presence of any tumor or metastasis of solid tumors, and had a significant effect on the agents. The prevalence of comorbidity in patients with MM at diagnosis was - 80%. The most common diseases have been associated disease of the gastrointestinal tract (88.4%), cardiovascular (78.6%), urinary (44.5%) and endocrine systems (26.8%). In assessing the prognostic impact on overall survival and an index of comorbidity Sharlson Freiburger index shows that both indices significantly affect the survival of patients with MM, depending on the increase in their score on the scales (P <0.001). Median survival in the evaluation of Freiburger index was 55.0, 29.5 and 19.5 months for 0, 1 and 2-3 scores, respectively. Sharlson comorbidity index also indicated a significant difference in the survival rate of patients corresponding to 0, 1-2, and ≥3 points.
Conclusion
so comorbidity patients affects the survival and effectiveness of treatment in patients with MM, reducing these figures.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma, Prognostic factor
Abstract: PB1993
Type: Publication Only
Background
Despite the modern possibilities of therapy, multiple myeloma (MM) is an incurable disease with a wide variety of outcomes, depending on the presence of risk factors. MM Classification based on the criteria of Durie/Salmon and the ISS, include, primarily, the risk factors associated with the disease itself. However, factors associated with the patient, such as co-morbidities and organ dysfunction which further affect the outcome of the tumor, is still not fully integrated into the predictive model.
Aims
To analyze the effect of prognostic factors: age, sex, medical condition and comorbidities, as well as indices of comorbidity and Sharlson Freiburger, overall survival (OS) in patients with MM.
Methods
206 patients with MM (91 men and 115 women) analyzed. Patients ranged in age from 36 to 81 years (median 68 years). The statistical analysis was used software package SPSS 23. Effect of studied factors on the long-term prognosis was estimated by odds ratios (confidence interval 0.95). In developing the model predicting the likelihood of an unfavorable outcome were used methods of correlation, factor and regression analysis.
Results
during the factor analysis, all investigated prognostic factors, such as somatic status, GFR <30 mL / min / 1.73 m2, the presence of any tumor or metastasis of solid tumors, and had a significant effect on the agents. The prevalence of comorbidity in patients with MM at diagnosis was - 80%. The most common diseases have been associated disease of the gastrointestinal tract (88.4%), cardiovascular (78.6%), urinary (44.5%) and endocrine systems (26.8%). In assessing the prognostic impact on overall survival and an index of comorbidity Sharlson Freiburger index shows that both indices significantly affect the survival of patients with MM, depending on the increase in their score on the scales (P <0.001). Median survival in the evaluation of Freiburger index was 55.0, 29.5 and 19.5 months for 0, 1 and 2-3 scores, respectively. Sharlson comorbidity index also indicated a significant difference in the survival rate of patients corresponding to 0, 1-2, and ≥3 points.
Conclusion
so comorbidity patients affects the survival and effectiveness of treatment in patients with MM, reducing these figures.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma, Prognostic factor
Type: Publication Only
Background
Despite the modern possibilities of therapy, multiple myeloma (MM) is an incurable disease with a wide variety of outcomes, depending on the presence of risk factors. MM Classification based on the criteria of Durie/Salmon and the ISS, include, primarily, the risk factors associated with the disease itself. However, factors associated with the patient, such as co-morbidities and organ dysfunction which further affect the outcome of the tumor, is still not fully integrated into the predictive model.
Aims
To analyze the effect of prognostic factors: age, sex, medical condition and comorbidities, as well as indices of comorbidity and Sharlson Freiburger, overall survival (OS) in patients with MM.
Methods
206 patients with MM (91 men and 115 women) analyzed. Patients ranged in age from 36 to 81 years (median 68 years). The statistical analysis was used software package SPSS 23. Effect of studied factors on the long-term prognosis was estimated by odds ratios (confidence interval 0.95). In developing the model predicting the likelihood of an unfavorable outcome were used methods of correlation, factor and regression analysis.
Results
during the factor analysis, all investigated prognostic factors, such as somatic status, GFR <30 mL / min / 1.73 m2, the presence of any tumor or metastasis of solid tumors, and had a significant effect on the agents. The prevalence of comorbidity in patients with MM at diagnosis was - 80%. The most common diseases have been associated disease of the gastrointestinal tract (88.4%), cardiovascular (78.6%), urinary (44.5%) and endocrine systems (26.8%). In assessing the prognostic impact on overall survival and an index of comorbidity Sharlson Freiburger index shows that both indices significantly affect the survival of patients with MM, depending on the increase in their score on the scales (P <0.001). Median survival in the evaluation of Freiburger index was 55.0, 29.5 and 19.5 months for 0, 1 and 2-3 scores, respectively. Sharlson comorbidity index also indicated a significant difference in the survival rate of patients corresponding to 0, 1-2, and ≥3 points.
Conclusion
so comorbidity patients affects the survival and effectiveness of treatment in patients with MM, reducing these figures.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma, Prognostic factor
{{ help_message }}
{{filter}}